Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

Experts explain what we know about the connection between gallstones and MASLD, and what you can do to reduce the risk of ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

The following is a summary of "Assessing the consistency of FIB-4, APRI, and GPR in evaluating significant liver fibrosis and ...

Incremental cardiometabolic risk factors — particularly diabetes, hypertension and high waist circumstance — were linked to ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Resmetirom is a medication approved by the FDA to treat adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with ...

In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Histoindex Pte Ltd. launched its laboratory-developed test for metabolic dysfunction-associated steatohepatitis (MASH), ...

PathAI, a global leader in AI-powered pathology, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted full qualification for ...